Cytonics on SeedInvest

Relief for Osteoarthritis

Raise to date: $429,344

Reporting Date: 06/02/2019

Key Stats

Minimum Raise

$25,000

Maximum Raise

$1,000,000

Likelihood of Max Unlikely
Start Date

04/05/2019

Stop Date

05/18/2019

Days Remaining

Closed

Security Type

Convertible Note

Investment Minimum

$1,000

Deal Type

Deal to Watch


Investment Summary

Status

Confirmed Closed

# of Investors

Not Known

% of Minimum Raised

1,717%

% of Maximum Raised

43%

Dollars Per Day to Reach Max

N/A

DPD* Committed

$9,985

DPD* Category

$2,802

DPD* All Companies

$1,080

Kingscrowd Momentum

$429,344

Total Dollars Raised

Commitments

Weekly Commitments ($)
Aggregate Commitments ($)

SEC Filing Data from Kingscrowd

Cytonics, with a valuation cap of $32.4 million, is raising Series C funding on SeedInvest. The company is a leader in regenerative medicine and has developed innovative therapies for musculoskeletal diseases like osteoarthritis. Cytonics has created an Autologous Platelet Integrated Concentration system that concentrates A2M from patients’ blood to treat their own damaged joints. Cytonics was founded by Gaetano Scuderi, a leading orthopedic surgeon with over 21 years of experience. The company has already raised $15 million in previous rounds of funding and the current crowdfunding round has a round size of $1 million. Cytonics has received $1.8 million in government grants from the NIH and has 6 issued and 9 pending patents.

INVEST NOW